# TransCon (transcon) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/transcon

> The FDA approved TransCon (transcon), sponsored by Ascendis Pharma A/S (ASND), on Aug 2024 for hypoparathyroidism in adults.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TransCon (transcon) |
| Codes |  |
| Sponsor | Ascendis Pharma A/S (ASND) https://sec-api.dev/companies/asnd/catalysts |
| Indications | [achondroplasia](https://sec-api.dev/indications/achondroplasia), in japan with hypoparathyroidism, [hypoparathyroidism in adults](https://sec-api.dev/indications/hypoparathyroidism-in-adults) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Mar 2022: topline data readout

- Status: completed, met. Date confidence: month. Stage: 3.
- First seen 2024-11-14, last confirmed 2025-11-12.
- SEC Form 8-K (accession 0001193125-25-277622): "In March 2022, we announced that top-line data from the randomized, double-blind, placebo-controlled portion of the Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism demonstrated statistically significant higher proportion of participants treated with TransCon PTH achieved the primary multi-component endpoint compared to placebo." https://www.sec.gov/Archives/edgar/data/1612042/000119312525277622/asnd-20250930.htm
- SEC Form 8-K (accession 0001612042-25-000006): "In March 2022, we announced that top-line data from the randomized, double-blind, placebo-controlled portion of the Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism demonstrated statistically significant higher proportion of participants treated with TransCon PTH achieved the primary multi-component endpoint compared to placebo." https://www.sec.gov/Archives/edgar/data/1612042/000161204225000006/asnd-20250630.htm
- SEC Form 8-K (accession 0000950170-25-061850): "In March 2022, we announced that top-line data from the randomized, double-blind, placebo-controlled portion of the Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism demonstrated statistically significant higher proportion of participants treated with TransCon PTH achieved the primary multi-component endpoint compared to placebo." https://www.sec.gov/Archives/edgar/data/1612042/000095017025061850/asnd-20250331.htm
- SEC Form 8-K (accession 0000950170-24-127079): "In March 2022, we announced that top-line data from the randomized, double-blind, placebo-controlled portion of the Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism demonstrated statistically significant higher proportion of participants treated with TransCon PTH achieved the primary multi-component endpoint compared to placebo." https://www.sec.gov/Archives/edgar/data/1612042/000095017024127079/asnd-20240930.htm
- SEC Form 10-K (accession 0000950170-25-018852): "In March 2022, we announced that top-line data from the randomized, double-blind, placebo-controlled portion of the Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism demonstrated statistically significant higher proportion of participants treated with TransCon PTH achieved the primary multi-component endpoint compared to placebo." https://www.sec.gov/Archives/edgar/data/1612042/000095017025018852/asnd-20241231.htm

### Apr 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2025-02-12, last confirmed 2026-02-11.
- SEC Form 10-K (accession 0001193125-26-046590): "For example, in April 2023 the FDA issued a Complete Response Letter in response to our original NDA submission for TransCon PTH, in which the FDA cited concerns related to the manufacturing control strategy for variability of delivered dose in the TransCon PTH drug/device combination product." https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm
- SEC Form 10-K (accession 0000950170-25-018852): "For example, in April 2023 the FDA issued a Complete Response Letter in response to our original NDA submission for TransCon PTH, in which the FDA cited concerns related to the manufacturing control strategy for variability of delivered dose in the TransCon PTH drug/device combination product." https://www.sec.gov/Archives/edgar/data/1612042/000095017025018852/asnd-20241231.htm

### Aug 2024: FDA approval

- Status: completed, approved. Date confidence: month. Indication: hypoparathyroidism in adults.
- First seen 2024-11-14, last confirmed 2024-11-14.
- SEC Form 8-K (accession 0000950170-24-127079): "In August 2024, the U.S. FDA approved TransCon PTH for the treatment of hypoparathyroidism in adults." https://www.sec.gov/Archives/edgar/data/1612042/000095017024127079/asnd-20240930.htm

### Dec 2024: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: in Japan with hypoparathyroidism.
- First seen 2025-01-13, last confirmed 2025-01-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-004905): "In December 2024, submitted a J-NDA to the Japanese medical authorities for TransCon PTH for the treatment of adults in Japan with hypoparathyroidism" https://www.sec.gov/Archives/edgar/data/1612042/000119312525004905/d923527dex991.htm

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: achondroplasia.
- First seen 2024-11-14, last confirmed 2025-05-01.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-110062): " Topline COACH combination trial (TransCon CNP + TransCon hGH) data expected in Q2 2025" https://www.sec.gov/Archives/edgar/data/1612042/000119312525110062/d795154dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-110062): "Topline Week 26 data from COACH, the combination TransCon CNP and TransCon hGH trial of children with achondroplasia (ages 2-11 years) expected in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1612042/000119312525110062/d795154dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-004905): "COACH Trial - first combination trial of TransCon hGH and TransCon CNP to further accelerate growth in achondroplasia; topline Week 26 data in children aged 2-11 expected in Q2 2025" https://www.sec.gov/Archives/edgar/data/1612042/000119312525004905/d923527dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-24-258608): "Expect topline Week 26 data from COACH, the combination TransCon hGH and TransCon CNP trial of children with achondroplasia (ages 2-11 years) in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1612042/000119312524258608/d827238dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-025103): "Topline Week 26 results from Phase 2 COACH Trial (TransCon CNP in combination with TransCon hGH) in children with achondroplasia expected in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1612042/000119312525025103/d840926dex991.htm
- SEC Form 8-K (accession 0001193125-25-004900): "Topline Week 26 results from Phase 2 COACH Trial (TransCon CNP in combination with TransCon hGH) expected in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1612042/000119312525004900/d906180d6k.htm

### February 28, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-11-26, last confirmed 2026-02-23.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-046736): "- TransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026" https://www.sec.gov/Archives/edgar/data/1612042/000119312526046736/d73635dex991.htm
- SEC Form 8-K (accession 0001193125-26-007934): "TransCon CNP is under Priority Review by the U.S. Food & Drug Administration ("FDA"), with a PDUFA target action date of February 28, 2026, and by the European Medicines Agency as a monotherapy for children with achondroplasia." https://www.sec.gov/Archives/edgar/data/1612042/000119312526007934/d27768d6k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-063954): "As a result of further information from the Company submitted to the FDA on November 5, 2025, related to the post-marketing requirement in response to the FDA's ongoing review of the NDA, the FDA has set a Prescription Drug User Fee Act ("PDUFA") goal date of February 28, 2026 to complete its review." https://www.sec.gov/Archives/edgar/data/1612042/000119312526063954/d112586dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-046736): "In the U.S., PDUFA action goal date of February 28, 2026 for pediatric achondroplasia." https://www.sec.gov/Archives/edgar/data/1612042/000119312526046736/d73635dex991.htm
- SEC Form 8-K (accession 0001193125-26-009636): "In the U.S., PDUFA goal date of February 28, 2026 for pediatric achondroplasia." https://www.sec.gov/Archives/edgar/data/1612042/000119312526009636/d13397d6k.htm
- SEC Form 8-K (accession 0001193125-25-297891): "Accordingly, the FDA has extended the Prescription Drug User Fee Act ("PDUFA") target action date by three months to February 28, 2026." https://www.sec.gov/Archives/edgar/data/1612042/000119312525297891/d24094d6k.htm
- SEC Form 10-K (accession 0001193125-26-046590): "As a result of further information from the Company submitted to the FDA on November 5, 2025, related to the post-marketing requirement in response to the FDA's ongoing review of the NDA, the FDA has set a Prescription Drug User Fee Act ("PDUFA") goal date of February 28, 2026 to complete its review." https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-063954): "Priority Review granted by U.S. FDA, PDUFA goal date February 28, 2026." https://www.sec.gov/Archives/edgar/data/1612042/000119312526063954/d112586dex992.htm

### Q3 2027: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-11-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-456989): "<2 years showing TransCon CNP stabilized or improved foramen magnum stenosis, and increased linear growth; topline pivotal data expected Q3 2027" https://www.sec.gov/Archives/edgar/data/1612042/000119312526456989/d80569dex991.htm

## Same indication

- [YORVIPATH (palopegteriparatide)](https://sec-api.dev/pdufa/palopegteriparatide) (ASND)
- [VOXZOGO (vosoritide)](https://sec-api.dev/pdufa/vosoritide) (BMRN)

Calendar months: [February 2026](https://sec-api.dev/fda-calendar/2026-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/transcon.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TransCon (transcon) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/transcon

```bibtex
@misc{secapidev_pdufa_transcon_20261116,
  title        = {TransCon (transcon) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/transcon}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_transcon_20261116","title":"TransCon (transcon) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/transcon","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
